Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease.

ABSTRACT: Parkinson's disease is one of the most common neurodegenerative disorders in elderly age. One of the mechanisms involved in the neurodegeneration appears related to the aggregation of the presynaptic protein alpha synuclein (α-syn) into toxic oligomers and fibrils. To date, no highly effective treatment is currently available; therefore, there is an increasing interest in the search of new therapeutic tools. The modulation of α-syn aggregation represents an emergent and promising disease-modifying strategy for reducing or blocking the neurodegenerative process. Herein, by combining in silico and in vitro screenings we initially identified 3-(cinnamylsulfanyl)-5-(4-pyridinyl)-1,2,4-triazol-4-amine (3) as α-syn aggregation inhibitor that was then considered a promising h

SUBMITTER: Vittorio S 

PROVIDER: S-EPMC7534360 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature